|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYRF |
Gene summary for MYRF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYRF | Gene ID | 745 |
| Gene name | myelin regulatory factor | |
| Gene Alias | 11orf9 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9Y2G1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 745 | MYRF | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.67e-13 | 6.66e-01 | -0.1808 |
| 745 | MYRF | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.55e-09 | 3.85e-01 | -0.0811 |
| 745 | MYRF | HTA11_347_2000001011 | Human | Colorectum | AD | 9.42e-04 | 1.90e-01 | -0.1954 |
| 745 | MYRF | HTA11_411_2000001011 | Human | Colorectum | SER | 4.62e-05 | 8.53e-01 | -0.2602 |
| 745 | MYRF | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.32e-08 | 5.12e-01 | -0.059 |
| 745 | MYRF | HTA11_866_3004761011 | Human | Colorectum | AD | 1.39e-05 | 2.70e-01 | 0.096 |
| 745 | MYRF | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.77e-04 | 4.00e-01 | 0.0528 |
| 745 | MYRF | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.79e-03 | 2.79e-01 | 0.0338 |
| 745 | MYRF | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.25e-03 | 1.80e-01 | 0.0674 |
| 745 | MYRF | S43 | Human | Liver | Cirrhotic | 6.54e-06 | 2.54e-01 | -0.0187 |
| 745 | MYRF | HCC1_Meng | Human | Liver | HCC | 1.49e-28 | -1.17e-01 | 0.0246 |
| 745 | MYRF | HCC2_Meng | Human | Liver | HCC | 1.08e-33 | 2.44e-01 | 0.0107 |
| 745 | MYRF | cirrhotic2 | Human | Liver | Cirrhotic | 2.37e-07 | 1.71e-01 | 0.0201 |
| 745 | MYRF | S027 | Human | Liver | HCC | 8.47e-10 | 8.76e-01 | 0.2446 |
| 745 | MYRF | S028 | Human | Liver | HCC | 4.72e-29 | 1.22e+00 | 0.2503 |
| 745 | MYRF | S029 | Human | Liver | HCC | 7.69e-24 | 1.10e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| GO:0043217 | Colorectum | AD | myelin maintenance | 9/3918 | 18/18723 | 5.82e-03 | 3.67e-02 | 9 |
| GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
| GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
| GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
| GO:0007009 | Colorectum | SER | plasma membrane organization | 36/2897 | 142/18723 | 1.50e-03 | 1.62e-02 | 36 |
| GO:00432171 | Colorectum | SER | myelin maintenance | 8/2897 | 18/18723 | 3.31e-03 | 2.83e-02 | 8 |
| GO:00516046 | Liver | Cirrhotic | protein maturation | 121/4634 | 294/18723 | 3.54e-10 | 1.68e-08 | 121 |
| GO:00164853 | Liver | Cirrhotic | protein processing | 85/4634 | 225/18723 | 9.01e-06 | 1.32e-04 | 85 |
| GO:0042063 | Liver | Cirrhotic | gliogenesis | 98/4634 | 301/18723 | 1.28e-03 | 8.60e-03 | 98 |
| GO:0010001 | Liver | Cirrhotic | glial cell differentiation | 75/4634 | 225/18723 | 2.24e-03 | 1.36e-02 | 75 |
| GO:0042552 | Liver | Cirrhotic | myelination | 46/4634 | 134/18723 | 8.04e-03 | 3.77e-02 | 46 |
| GO:0048709 | Liver | Cirrhotic | oligodendrocyte differentiation | 34/4634 | 95/18723 | 1.06e-02 | 4.66e-02 | 34 |
| GO:0007272 | Liver | Cirrhotic | ensheathment of neurons | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:0008366 | Liver | Cirrhotic | axon ensheathment | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:001648511 | Liver | HCC | protein processing | 121/7958 | 225/18723 | 4.01e-04 | 2.71e-03 | 121 |
| GO:00072721 | Liver | HCC | ensheathment of neurons | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00083661 | Liver | HCC | axon ensheathment | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00425521 | Liver | HCC | myelination | 71/7958 | 134/18723 | 9.08e-03 | 3.49e-02 | 71 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYRF | SNV | Missense_Mutation | novel | c.1039A>C | p.Asn347His | p.N347H | Q9Y2G1 | protein_coding | deleterious(0.03) | probably_damaging(0.988) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| MYRF | SNV | Missense_Mutation | novel | c.2066N>G | p.Thr689Arg | p.T689R | Q9Y2G1 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MYRF | SNV | Missense_Mutation | novel | c.1432N>T | p.Arg478Trp | p.R478W | Q9Y2G1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYRF | SNV | Missense_Mutation | c.2162N>T | p.Ser721Leu | p.S721L | Q9Y2G1 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
| MYRF | SNV | Missense_Mutation | novel | c.241N>A | p.Gly81Arg | p.G81R | Q9Y2G1 | protein_coding | tolerated(0.2) | possibly_damaging(0.77) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| MYRF | SNV | Missense_Mutation | c.499N>C | p.Cys167Arg | p.C167R | Q9Y2G1 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MYRF | SNV | Missense_Mutation | c.607C>T | p.Arg203Trp | p.R203W | Q9Y2G1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CA-5254-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| MYRF | SNV | Missense_Mutation | rs747836674 | c.52N>A | p.Asp18Asn | p.D18N | Q9Y2G1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| MYRF | SNV | Missense_Mutation | c.1709C>T | p.Ala570Val | p.A570V | Q9Y2G1 | protein_coding | deleterious(0) | benign(0.356) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MYRF | SNV | Missense_Mutation | novel | c.1174N>A | p.Asp392Asn | p.D392N | Q9Y2G1 | protein_coding | deleterious(0) | benign(0.125) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |